181 related articles for article (PubMed ID: 34153718)
1. NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature.
Osumi H; Vecchione L; Keilholz U; Vollbrecht C; Alig AHS; von Einem JC; Stahler A; Striefler JK; Kurreck A; Kind A; Modest DP; Stintzing S; Jelas I
Eur J Cancer; 2021 Aug; 153():86-95. PubMed ID: 34153718
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy-induced Reversion of Mutant
Sato S; Mikayama YO; Shiozawa M; Nukada S; Iguchi K; Okamoto H; Kohmura T; Kazama K; Tanaka K; Oshima T; Rino Y
Anticancer Res; 2022 May; 42(5):2625-2635. PubMed ID: 35489751
[TBL] [Abstract][Full Text] [Related]
3. A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer.
Osumi H; Takashima A; Ooki A; Yoshinari Y; Wakatsuki T; Hirano H; Nakayama I; Okita N; Sawada R; Ouchi K; Fukuda K; Fukuoka S; Ogura M; Takahari D; Chin K; Shoji H; Kato K; Ishizuka N; Boku N; Yamaguchi K; Shinozaki E
Transl Oncol; 2023 Sep; 35():101718. PubMed ID: 37364334
[TBL] [Abstract][Full Text] [Related]
4. Anti-epidermal growth factor receptor treatment for patients with Neo
Harada K; Yuki S; Kawamoto Y; Nakamura T; Kaneko S; Ishida K; Sakamoto N; Komatsu Y
Ther Adv Med Oncol; 2023; 15():17588359231216090. PubMed ID: 38033418
[TBL] [Abstract][Full Text] [Related]
5. Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol.
Osumi H; Ishizuka N; Takashima A; Kumekawa Y; Nakano D; Shiozawa M; Denda T; Sawada R; Ouchi K; Wakatsuki T; Narikazu B; Kato K; Yamaguchi K; Shinozaki E
BMJ Open; 2022 Sep; 12(9):e063071. PubMed ID: 36581973
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies in the treatment of metastatic colorectal cancer: a review.
Tol J; Punt CJ
Clin Ther; 2010 Mar; 32(3):437-53. PubMed ID: 20399983
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA expression profiling identifies miR-31-5p/3p as associated with time to progression in wild-type RAS metastatic colorectal cancer treated with cetuximab.
Mlcochova J; Faltejskova-Vychytilova P; Ferracin M; Zagatti B; Radova L; Svoboda M; Nemecek R; John S; Kiss I; Vyzula R; Negrini M; Slaby O
Oncotarget; 2015 Nov; 6(36):38695-704. PubMed ID: 26497852
[TBL] [Abstract][Full Text] [Related]
8. Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer.
Albuquerque J; Neto da Silva D; Padrão T; Leal-Costa L; Bizarro R; Correia J; Baptista C; Machete M; Prazeres G; Margarido I; Fernandes G; Simões P; Timóteo T; Lopes F; Godinho J; Moreira-Pinto J; Rodrigues T; Faria A; Pulido C; Cirnes L; Teixeira JA; Passos Coelho JL
Oncologist; 2024 Mar; 29(3):e337-e344. PubMed ID: 38071748
[TBL] [Abstract][Full Text] [Related]
9. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
[TBL] [Abstract][Full Text] [Related]
10. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
11. Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer.
Graham CN; Hechmati G; Fakih MG; Knox HN; Maglinte GA; Hjelmgren J; Barber B; Schwartzberg LS
J Med Econ; 2015; 18(8):619-28. PubMed ID: 25822327
[TBL] [Abstract][Full Text] [Related]
12. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
Toledo RA; Cubillo A; Vega E; Garralda E; Alvarez R; de la Varga LU; Pascual JR; Sánchez G; Sarno F; Prieto SH; Perea S; Lopéz-Casas PP; López-Ríos F; Hidalgo M
Oncotarget; 2017 May; 8(21):35289-35300. PubMed ID: 27852040
[TBL] [Abstract][Full Text] [Related]
13. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
[TBL] [Abstract][Full Text] [Related]
14. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies.
Yoshida M; Shimura T; Sato M; Ebi M; Nakazawa T; Takeyama H; Joh T
J Cancer Res Clin Oncol; 2013 Mar; 139(3):367-78. PubMed ID: 23099994
[TBL] [Abstract][Full Text] [Related]
15. Rationale for and Design of the PARADIGM Study: Randomized Phase III Study of mFOLFOX6 Plus Bevacizumab or Panitumumab in Chemotherapy-naïve Patients With RAS (KRAS/NRAS) Wild-type, Metastatic Colorectal Cancer.
Yoshino T; Uetake H; Tsuchihara K; Shitara K; Yamazaki K; Oki E; Sato T; Naitoh T; Komatsu Y; Kato T; Yamanaka K; Iwasaki K; Soeda J; Hihara M; Yamanaka T; Ochiai A; Muro K
Clin Colorectal Cancer; 2017 Jun; 16(2):158-163. PubMed ID: 28237539
[TBL] [Abstract][Full Text] [Related]
16. Randomized study of FOLFIRI plus either panitumumab or bevacizumab for wild-type KRAS colorectal cancer-WJOG 6210G.
Shitara K; Yonesaka K; Denda T; Yamazaki K; Moriwaki T; Tsuda M; Takano T; Okuda H; Nishina T; Sakai K; Nishio K; Tokunaga S; Yamanaka T; Boku N; Hyodo I; Muro K
Cancer Sci; 2016 Dec; 107(12):1843-1850. PubMed ID: 27712015
[TBL] [Abstract][Full Text] [Related]
17. A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer.
Garrido-Laguna I; McGregor KA; Wade M; Weis J; Gilcrease W; Burr L; Soldi R; Jakubowski L; Davidson C; Morrell G; Olpin JD; Boucher K; Jones D; Sharma S
Invest New Drugs; 2013 Oct; 31(5):1257-64. PubMed ID: 23504398
[TBL] [Abstract][Full Text] [Related]
18. Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol.
Chen SH; Tsai HL; Jiang JK; Sung YC; Huang CW; Yeh YM; Chen LT; Wang JY
BMC Cancer; 2019 Jun; 19(1):640. PubMed ID: 31253124
[TBL] [Abstract][Full Text] [Related]
19. Undetectable
Bouchahda M; Saffroy R; Karaboué A; Hamelin J; Innominato P; Saliba F; Lévi F; Bosselut N; Lemoine A
JCO Precis Oncol; 2020; 4():. PubMed ID: 33015528
[TBL] [Abstract][Full Text] [Related]
20. PIK3CA exon 20 mutations as a potential biomarker for resistance to anti-EGFR monoclonal antibodies in KRAS wild-type metastatic colorectal cancer: a systematic review and meta-analysis.
Mao C; Yang ZY; Hu XF; Chen Q; Tang JL
Ann Oncol; 2012 Jun; 23(6):1518-25. PubMed ID: 22039088
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]